The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year.
A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.
Tolero's investigational agent dubermatinib will be evaluated in AML patients who harbor a TP53 mutation and/or a complex karyotype.
In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.
The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.
